Latham & Watkins Advises Blackbird on Sale of its Stake in Cygna Labs

Cross-border team represents US venture capital investor in sale of its remaining stake in provider of compliance software solutions.

September 11, 2020

Latham & Watkins LLP has advised US venture capital investor Blackbird Ventures (Blackbird) on the sale of its remaing stake in Cygna Labs, a leading provider of compliance software solutions, to n3k Informatik (n3k), a VR Equitypartner portfolio company. Latham had already advised Blackbird in 2018 on the sale of its majority stake in Cygna Labs to n3k. Financial details remain confidential.

Blackbird incubates, and invests in, early-stage technology companies, providing operational support along the entire startup trajectory to develop market-transforming businesses.

Latham & Watkins LLP represented Blackbird with a corporate team led by Hamburg partner Stefan Widder, with Washington, D.C. counsel Joseph Simei, and Hamburg associates Jacob Ahme and Maximilian Berenbrok.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.